Table 4.
Reference standard | Total, n | Positive samples, N | Sensitivity (95% CI) | Specificity (95% CI) |
---|---|---|---|---|
NPS RT-PCR ≥ 2 targets | 1718 | 88 | 35% (26–45) | 97% (96–98) |
Symptoms | 691 | 47 | 34% (24–46) | 96% (95–98) |
No symptoms | 1027 | 41 | 36% (21–54) | 97% (96–98) |
NPS RT-PCR ≥ 1 target and Ct value < 32 | 1718 | 88 | 37% (27–47) | 97% (96–98) |
Symptoms | 691 | 47 | 36% (24–49) | 96% (94–98) |
No symptoms | 1027 | 41 | 38% (22–56) | 97% (96–98) |
Saliva RT-PCR ≥ 1 target | 1640 | 85 | 30% (23–38) | 97% (96–98) |
Symptoms | 662 | 45 | 28% (19–38) | 96% (95–98) |
No symptoms | 978 | 40 | 33% (22–47) | 98% (97–99) |
NPS RT-PCR ≥ 1 target or Saliva RT-PCR ≥ 1 target | 1648 | 87 | 28% (22–36) | 97% (96–98) |
Symptoms | 667 | 47 | 27% (19–37) | 97% (95–98) |
No symptoms | 981 | 40 | 30% (20–43 | 98% (97–99) |
NPS RT-PCR ≥ 1 target or Saliva RT-PCR ≥ 1 target and Ct value < 32 | 1646 | 87 | 34% (26–42) | 97% (96–98) |
Symptoms | 666 | 47 | 30% (21–41) | 97% (95–98) |
No symptoms | 980 | 40 | 40% (26–55) | 98% (97–99) |
NPS antigen | 1474 | 79 | 37% (28–47) | 97% (96–98) |
Symptoms | 652 | 45 | 35% (24–46) | 97% (95–98) |
No symptoms | 822 | 34 | 44% (26–62) | 97% (96–98) |
95% CI 95% confidence interval.